Miransertib

DB14982InvestigationalSmall molecule

Miransertib is under investigation in clinical trial NCT01473095 (Phase 1 Dose Escalation Study of ARQ 092 in Adult Subjects With Advanced Solid Tumors and Recurrent Malignant Lymphoma).

Chemical structure of Miransertib
Formula / weight
C27H24N6 · 432.531 g/mol (avg)
Also known as
3-{3-[4-(1-aminocyclobutyl)phenyl]-5-phenyl-3H-imidazo[4,5-b]pyridin-2-yl}pyridin-2-amine
Code names
ARQ 092 · MK-7075

Resolves to

Compound
UNIIT1DQI1B52YCAS1313881-70-7ChEMBLCHEMBL4297188
Structure
InChIKeyHNFMVVHMKGFCMB-UHFFFAOYSA-NSMILESNC1=NC=CC=C1C1=NC2=CC=C(N=C2N1C1=CC=C(C=C1)C1(N)CCC1)C1=CC=CC=C1
Targets
P31749AKT1Q9Y243AKT3

What you can answer from here — as of April 23, 2025

2Protein targetsEach mapped to UniProt, with action and pharmacological action
Listed above
7Clinical trialsPhase, status and sponsor resolved per trial
Sign in
6+ReferencesStructured and connected to the statements they support
Sign in

Which drugs share a target with Miransertib, and which of those have an active Phase 3 trial?

Answer this in Biopharma OSSign in to your account

Create a free account or log in to explore the full data card.

Create Account
Log InPaid Account Log In